Independent Director Determination

8 DECEMBER 2025



INDEPENDENT DIRCTOR DETERMINATION – NZX LISTING RULE 2.6
Pacific Edge Limited – Independent Director Determination
As required by NZX Listing Rule 2.6.1 and 2.6.2, the Board of Pacific Edge Limited has
determined that Simon Richard Flood is an Independent Director for the purposes of the NZX
Listing Rules.
Background
Simon Richard Flood was appointed to the Board on 4 December 2025. The Board has
considered the range of factors outlined in the NZX Corporate Governance Code (including
any interests, relationships, or positions that could reasonably influence the Director’s ability to
act independently).
In the Board’s judgment, there are no relationships or interests that materially compromise or
could reasonably be perceived to compromise the Director’s independence. Accordingly,
Simon Richard Flood is classified as an Independent Director under the NZX Listing Rules.
Contact for Further Information:
Grant Gibson 
Chief Financial Officer 
Pacific Edge Ltd 
P: +64 (3) 479 5800 
OVERVIEW
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way
in the development and commercialization of bladder cancer diagnostic and prognostic tests
for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in
Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its
wholly owned, and CLIA certified, laboratories in New Zealand and the USA.
Cxbladder: www.cxbladder.com
Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of
urothelial cancer in patients presenting with microhematuria and those being monitored for
recurrent disease. The tests help improve the overall patient experience, while prioritizing time
and clinical resources to optimize practice workflow and improve efficiency.
Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than
25 peer reviewed publications, and Cxbladder Triage is now included in the American
Urological Association’s Microhematuria Guideline. To drive increased adoption and improved
patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies
designed to generate further clinical utility evidence.

2

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and
South America. In the US, the test has been used by over 5,000 urologists who have ordered
more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the
population via public healthcare and all residents have the option of buying the test online.